WeVote

Bill

Bill

SB 1011

AN ACT REGULATING REBATES BY PHARMACY BENEFITS MANAGERS.

2025 Regular Session Introduced by Heather Somers

Connecticut bill requires pharmacy benefit managers to disclose and potentially redirect rebates from drug manufacturers to consumers, aiming to lower prescription drug costs and increase pricing transparency.

REF. TO JOINT COMM. ON Insurance and Real Estate
0
WeVote Research Nonpartisan
Bill Summary · SB 1011

Legislative bill overview

SB 1011 establishes regulations governing how pharmacy benefit managers (PBMs) handle rebates—discounts negotiated with drug manufacturers. The bill aims to increase transparency and potentially require PBMs to pass certain rebate savings along to consumers or insurers rather than retaining them as profit. Connecticut would join several other states that have implemented PBM rebate restrictions.

Why is this important

PBMs control which drugs are covered and at what cost, wielding significant power in prescription pricing. Because PBMs often keep substantial rebates from drug manufacturers while consumers and insurers pay high list prices, this creates a disconnect between negotiated discounts and actual out-of-pocket costs. The bill addresses a key driver of high pharmaceutical costs that affects insurance premiums, copays, and medication access.

Potential points of contention

  • PBM opposition: PBMs argue rebates fund their operations and that mandating pass-through of rebates would reduce their negotiating leverage with manufacturers, potentially raising drug prices overall
  • Implementation complexity: Defining which rebates must be passed through, to whom, and how could create administrative burden and unintended market consequences
  • Effectiveness uncertainty: Evidence is mixed on whether rebate pass-through requirements actually lower costs for consumers versus just redistributing money between industry players

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.